These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

42 related articles for article (PubMed ID: 3502367)

  • 21. Resistance to nalidixic acid. A misconception due to underdosage.
    Stamey TA; Bragonje J
    JAMA; 1976 Oct; 236(16):1857-60. PubMed ID: 989536
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mechanisms of action of and resistance to ciprofloxacin.
    Hooper DC; Wolfson JS; Ng EY; Swartz MN
    Am J Med; 1987 Apr; 82(4A):12-20. PubMed ID: 3034057
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Studies on the interaction of 4-quinolones with DNA by DNA unwinding experiments.
    Tornaletti S; Pedrini AM
    Biochim Biophys Acta; 1988 Mar; 949(3):279-87. PubMed ID: 2831987
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparative in vitro antistaphylococcal effect of norfloxacin and pefloxacin on 312 hospital strains].
    Ronco E; Pilliot J
    Pathol Biol (Paris); 1985 May; 33(5):381-4. PubMed ID: 3162139
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Evaluation of the effect of new fluoroderivatives of piperazinol-quinoline on clinical strains of aerobic and anaerobic bacteria].
    Dzierzanowska D; Ukraiński W; Piotrowska E; Kazmirowska Z; Pykiel M
    Pol Tyg Lek; 1986 Sep; 41(37):1180-3. PubMed ID: 3822880
    [No Abstract]   [Full Text] [Related]  

  • 26. [Comparison of the antibacterial effects of ofloxacin, oxolinic acid and nalidixic acid].
    Langsádl L; Menkyna R; Golier J; Silan L
    Cesk Epidemiol Mikrobiol Imunol; 1988 Sep; 37(5):297-308. PubMed ID: 3197127
    [No Abstract]   [Full Text] [Related]  

  • 27. [Susceptibility to quinolones of Salmonella isolated from men and animals].
    Avril JL; Couete I; Travert MF; Autuly F; Plessis P
    Pathol Biol (Paris); 1995 Apr; 43(4):270-3. PubMed ID: 7567113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A new screening method for proof of R factors transfer.
    Bohus J
    J Hyg Epidemiol Microbiol Immunol; 1974; 18(2):202-11. PubMed ID: 4606127
    [No Abstract]   [Full Text] [Related]  

  • 29. Antiviral activity of gyrase inhibitors norfloxacin, coumermycin A1 and nalidixic acid.
    Ferrazzi E; Peracchi M; Biasolo MA; Faggionato O; Stefanelli S; Palù G
    Biochem Pharmacol; 1988 May; 37(9):1885-6. PubMed ID: 2837249
    [No Abstract]   [Full Text] [Related]  

  • 30. The quinolones.
    Lancet; 1984 Jan; 1(8367):24-5. PubMed ID: 6140347
    [No Abstract]   [Full Text] [Related]  

  • 31. [Quinolones: antimicrobials for the 90s].
    Timerman A
    AMB Rev Assoc Med Bras; 1987; 33(5-6):81-2. PubMed ID: 3502367
    [No Abstract]   [Full Text] [Related]  

  • 32. [Comparative bacteriologic activity of norfloxacin, ofloxacin and pefloxacin against 320 Gram-negative bacilli resistant and non-resistant to nalidixic acid and cephalosporins].
    Croize J; Le Noc P; Bryskier A; Robert J
    Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):564-8. PubMed ID: 3937128
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vitro comparison of norfloxacin with nalidixic acid, cinoxacin and oxolinic acid.
    Vuye A
    Arzneimittelforschung; 1983; 33(12):1623-7. PubMed ID: 6230083
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The comparative in vitro activity of ofloxacin (RU 43 280) and other quinolone derivatives against 722 bacteria of clinical interest.
    Santos Ferreira M; Vital J
    Chemioterapia; 1987 Jun; 6(2 Suppl):145-7. PubMed ID: 2908239
    [No Abstract]   [Full Text] [Related]  

  • 35. [Antibacterial activity of norfloxacin, ofloxacin and ciprofloxacin according to resistance phenotypes to nalidixic acid and pefloxacin].
    Soussy CJ; Le Van Thoi J; Duval J
    Pathol Biol (Paris); 1990 May; 38(5):376-84. PubMed ID: 2367152
    [TBL] [Abstract][Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.